In AML, the European Leukemia Net (ELN) classification system poorly discriminates aza/ven outcomes and alternative patterns of mutations involving TP53, FLT3 internal tandem duplication (FLT3-ITD), KRAS and NRAS mutations were suggested to categorize pts into higher-, intermediate-, and lower-benefit groups [36]. This evidence concerns the gene FLT3 and acute myeloid leukemia.